Overview
The goal of this randomised controlled trial is to determine the effect of consuming a multistrain probiotic OMNi-BiOTiC® Hetox on improving the healing, pain management, and postsurgical complications after neurosurgery.
The main question it aims to answer is:
• Is the multistrain probiotic OMNi-BiOTiC® Hetox effective in in improving patient-reported disability after neurosurgery?
Researchers will compare the probiotic group and the placebo group to determine if the healing is significantly different between the groups.
Eligibility
Inclusion Criteria:
- adults with MRI-confirmed disc herniation, stenosis, or instability of the lumbar or cervical spine.
- Able to provide written informed consent
- Willing to comply with study procedures and follow-up assessments
- No contraindications to probiotic administration
Exclusion Criteria:
- symptoms of acute infection (vomiting, fever above 38°C, diarrhea, respiratory symptoms),
- chronic diseases,
- use of probiotics one month before inclusion.